Arch Esp Urol 2017 Apr;70(3):336-341
UGC Urología. Complejo Hospitalario Universitario Granada (CHUG). Instituto de Investigación Biosanitaria IBS. Granada. Universidad de Granada. España.
Bull Cancer 2014 Sep;101(9):832-40
Oncologie médicale, Hôpital Saint-André, 33000 Bordeaux, France, Early Drug Development Certified Unit (Inserm-CIC/INCa), 33075 Bordeaux, France.
Sunitinib was the first targeted therapy improving progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) in the first line of treatment. Classically, sunitinib is administered at a dose of 50 mg/day during four weeks followed by two weeks off (schedule 4/6). This schedule has two pitfalls: intermittent exposure with two weeks "off" and the increase in toxicity during the fourth week. Read More
J Clin Oncol 2009 Sep 3;27(25):4068-75. Epub 2009 Aug 3.
Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.
Purpose: Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen.
Patients And Methods: Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Read More
Eur Urol 2011 Sep 17;60(3):448-54. Epub 2011 May 17.
Bart Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital London, UK.
Background: The role of cytoreductive nephrectomy in metastatic clear cell renal cell carcinoma (ccRCC) is controversial.
Objective: To determine the outcome of patients with metastatic ccRCC who receive sunitinib prior to planned nephrectomy.
Design, Setting, And Participants: The study combined the data from two prospective phase 2 studies that assessed upfront sunitinib (12-16 wk) prior to nephrectomy in previously untreated patients with metastatic renal cell carcinoma (RCC). Read More
Ann Oncol 2015 Oct 27;26(10):2107-13. Epub 2015 Jul 27.
Institut Gustave Roussy/Medical Oncology Department, Paris, France.
Background: First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and 1-week-off (2/1 schedule), might improve tolerability. We evaluated the safety and outcomes of this schedule in a large multicenter analysis. Read More